U.S. Markets open in 10 mins

TESARO Receives Positive CHMP Opinion for ZEJULA®

ZUG, Switzerland, Sept. 15, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (TSRO), an oncology-focused biopharmaceutical company, today announced that the European Medicines Agency`s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for the Company`s marketing authorization application (MAA) for ZEJULA®(niraparib) as a monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete response (CR) or partial response (PR) to platinum-based chemotherapy. This opinion will now be referred to the European Commission (EC), which grants marketing authorization for medicines in the European Union. Pending the decision by the EC, ZEJULA would be the first oral, once-daily poly (ADP-ribose) polymerase (PARP) 1/2 inhibitor approved in Europe for use in patients regardless of BRCA mutation or biomarker status.

ZEJULA was approved by the Food and Drug Administration (FDA) on March 27, 2017 and is marketed by TESARO in the United States, where it is the most frequently prescribed PARP inhibitor.

"ZEJULA was studied with the highest level of clinical rigor, and the Phase 3 NOVA trial generated unsurpassed efficacy results in patients with recurrent ovarian cancer, including women without germline BRCA mutations who have the most challenging prognosis and few treatment options," said Mary Lynne Hedley, Ph.D., President and COO of TESARO. "Today`s positive CHMP opinion brings us one step closer to providing this important new medicine to a broad population of patients with recurrent ovarian cancer in Europe." 

The ZEJULA marketing authorization application is supported by data from the ENGOT-OV16/NOVA trial, a double-blind, placebo-controlled, international Phase 3 study of ZEJULA that enrolled 553 patients with recurrent ovarian cancer who had achieved either a PR or CR to their most recent platinum-based chemotherapy. Approximately two-thirds of study participants did not have germline BRCA mutations. Progression in the NOVA study was determined by robust, unbiased, blinded central review to be the earlier of radiographic or clinical progression. ZEJULA significantly increased progression free survival (PFS) in patients with and without germline BRCA mutations as compared to the control arm. Treatment with ZEJULA reduced the risk of disease progression or death by 73% in patients with germline BRCA mutations (HR 0.27) and by 55% in patients without germline BRCA mutations (HR 0.45). The magnitude of benefit was similar for patients entering the trial with a PR or a CR.

The most common grade 3/4 adverse reactions to ZEJULA in the NOVA trial included thrombocytopenia (34%), anemia (25%), neutropenia (20%), and hypertension (9%). Following dose adjustment based on individual tolerability, the incidence of grade 3/4 thrombocytopenia was low; approximately 1% after month two. The majority of hematologic adverse events were successfully managed via dose modification, and discontinuation of therapy due to thrombocytopenia, neutropenia and anemia occurred in 3.3%, 1.9% and 1.4% of patients, respectively.

"This is an important milestone for TESARO, marking our second positive CHMP opinion for our portfolio in 2017. We are rapidly globalizing the Company`s mission of providing transformative oncology therapies to those who need them most," said Orlando Oliveira, Senior Vice President and General Manager of TESARO International. "Upon final approval by the EC, we intend to launch ZEJULA across multiple countries in Europe where we already have an established, direct presence, beginning in the fourth quarter."

About Ovarian Cancer in Europe
Europe has one of the highest incidences of ovarian cancer in the world with approximately 45,000 women diagnosed there every year1,[2]. Ovarian cancer affects approximately 1.3 in 10,000 people in the European Union, where it is the sixth-most common cancer among women and the fifth-most frequent cause of cancer death among women3,[4]. Despite high initial response rates to platinum-based chemotherapy, approximately 85% of women with advanced ovarian cancer will experience a recurrence of the disease after first-line treatment. The efficacy of chemotherapy also diminishes over time.

TESARO is an oncology-focused biopharmaceutical company devoted to providing transformative therapies to people bravely facing cancer. For more information, visit www.tesarobio.com and follow us on Twitter and LinkedIn.

About ZEJULA (niraparib)
ZEJULA is an oral, once-daily poly (ADP-ribose) polymerase (PARP) 1/2 inhibitor that is indicated in the U.S. for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. The National Comprehensive Cancer Network (NCCN) added ZEJULA to the NCCN Clinical Practice Guidelines in Oncology Ovarian Cancer version 1.2017-April 12, 2017-as maintenance therapy for patients with platinum-sensitive disease who are in partial or complete response after completion of two or more lines of platinum-based chemotherapy. In preclinical studies, ZEJULA concentrates in the tumor relative to plasma, delivering greater than 90% durable inhibition of PARP 1/2 and a persistent antitumor effect.

Forward Looking Statements
To the extent that statements contained in this press release are not descriptions of historical facts regarding TESARO, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "anticipate," "estimate," "intend," and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this release involve substantial risks and uncertainties that could cause our clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, risks associated with competition in the PARP market, risks related to pricing and reimbursement, risks related to manufacturing and supply, risks related to intellectual property, and other risks and uncertainties that could affect the availability or commercial potential of ZEJULA. TESARO undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see TESARO`s Annual Report on Form 10-K for the year ended December 31, 2016 and Quarterly Report on Form 10-Q for the quarter ended June 30, 2017.


1 World Cancer Research Fund International. http://www.wcrf.org (Last accessed 14 September 2017)

2 EUCAN (EU, EEA and Switzerland). http://eco.iarc.fr/eucan/CancerOne.aspx?Cancer=27&Gender=2 (Last accessed 14 September 2017)

3 EUCAN. http://eco.iarc.fr/eucan/CancerOne.aspx?Cancer=27&Gender=2  (Last accessed 14 September 2017)

4 CDC, https://www.cdc.gov/cancer/ovarian/statistics/index.htm (Last accessed 14 September 2017)

Global Media & Investor Contact: 
Jennifer Davis 
Vice President, Corporate Communications & Investor Relations 
+1.781.325.1116 or jdavis@tesarobio.com

Ex-U.S. Media Contact: 
Shannon Altimari 
Head of Corporate Affairs, International 
+41 (0) 41 588 08 68 or saltimari@tesarobio.com 

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: TESARO, Inc. via GlobeNewswire


  • Business
    Thomson Reuters StreetEvents

    Edited Transcript of MTY.TO earnings conference call or presentation 12-Jul-19 12:30pm GMT

    Q2 2019 MTY Food Group Inc Earnings Call

  • Kite Realty Group Trust (NYSE:KRG) Investors Should Think About This Before Buying It For Its Dividend
    Simply Wall St.

    Kite Realty Group Trust (NYSE:KRG) Investors Should Think About This Before Buying It For Its Dividend

    Today we'll take a closer look at Kite Realty Group Trust (NYSE:KRG) from a dividend investor's perspective. A high yield and a long history of paying dividends is an appealing combination for Kite Realty Group Trust. There are a few simple ways to reduce the risks of buying Kite Realty Group Trust for its dividend, and we'll go through these below.

  • Business
    Financial Times

    Why companies like Ocado produce gobbledegook

    p Ocado, the UK supermarket delivery company, attracted some online ridicule last week for this statement that it published with its half-year results: p “Over the last six months, the centre of gravity at Ocado Group has shifted from our heritage as an iconic and much-loved domestic pure-play online grocer to our future as a technology-driven global software and robotics platform business, providing a unique and proprietary end-to-end solution for online grocery, and an innovation factory, applying our technology...

  • Business
    Motley Fool

    Canopy Growth Just Confirmed What We've Long Suspected

    Perhaps none more so than the largest marijuana stock in the world by market cap, Canopy Growth (NYSE: CGC). As expected, Canopy Growth won't be profitable in fiscal 2020 Last week, Wall Street investment firm Jefferies, which offers the tamest growth outlook for the global cannabis industry at $50 billion in sales by 2029, met with Canopy Growth's chief financial officer, Mike Lee, who was appointed to his post less than two months ago. Although a number of topics were covered, as noted by Jefferies' covering analyst Andrew Bennett, one important piece of information came to light that confirmed a suspicion I and most of Wall Street have had for quite some time: Canopy Growth won't be profi...

  • AMD earnings: What to expect

    AMD earnings: What to expect

    Advanced Micro Devices Inc. is the chip maker to watch this earnings season, as the company takes on Intel Corp. and Nvidia Corp. amid problems in the sector that are expected to show signs of improvement. Earnings: Of the 29 analysts surveyed by FactSet, AMD on average is expected to post adjusted earnings of 8 cents a share, down from the 9 cents a share expected at the beginning of the quarter. Revenue: Wall Street expects revenue of $1.52 billion from AMD, according to 28 analysts polled by FactSet.

  • 3 Drug Stocks With Unimaginably Low P/E Ratios
    Motley Fool

    3 Drug Stocks With Unimaginably Low P/E Ratios

    While there are plenty of brand-name companies valued at reasonably low current and forward P/E ratios ("forward" meaning the P/E ratio based on next fiscal year's estimated earnings per share (EPS)), it's interestingly the healthcare sector that's home to three of the most unimaginable low P/E ratios that you'll come across. But as you'll see, while these low P/E ratios may offer value, they're often low for a very good reason. Mallinckrodt: 2019 P/E of 1 Trust me, most folks would do a double take if you told them that there's a stock out there that recently upped its full-year earnings forecast to $8.30 to $8.60 per share but closed this past weekend at $8.59 a share.

  • AbbVie Buys Allergan for $63 Billion
    Meredith Videos

    AbbVie Buys Allergan for $63 Billion

    Allergan is the maker of Botox.

  • Business

    Bank of America plans to boost dividend 20%, increase pace of stock buybacks

    Bank of America Corp. (bac) announced Wednesday a plan to return $37 billion to shareholders over the next 12 months, through share repurchases and dividends. As part of that plan, the money-center bank said it plans to increase the quarterly dividend by 20%. Based on Tuesday's stock closing price of $28.99 and the current dividend of 15 cents a share, a 20% increase would imply a quarterly dividend of 18 cents a share, an annual dividend rate of 72 cents a share and a dividend yield of 2.48%.

  • A Look At The Fair Value Of Woodward, Inc. (NASDAQ:WWD)
    Simply Wall St.

    A Look At The Fair Value Of Woodward, Inc. (NASDAQ:WWD)

    In this article we are going to estimate the intrinsic value of Woodward, Inc. (NASDAQ:WWD) by taking the expected future cash flows and discounting them to today's value. This is done using the Discounted Cash Flow (DCF) model. Remember though, that there are many ways to estimate a company's value, and a DCF is just one method.

  • Another 2.2 million patients affected by AMCA data breach

    Another 2.2 million patients affected by AMCA data breach

    Another clinical lab ensnared in the AMCA data breach has come forward. Clinical Pathology Laboratories (CPL) says 2.2 million patients may have had their names, addresses, phone numbers, dates of birth, dates of service, balance information and treatment provider information stolen in the previously-reported breach. Another 34,500 patients had their credit card or banking information compromised.

  • Square's Most Valuable New Product of 2019
    Motley Fool

    Square's Most Valuable New Product of 2019

    And while Square's subscription and services revenue is anchored by Cash App, Square Capital, Caviar, and Instant Deposit, the Square Card may be a catalyst for further growth in the segment as well as fueling growth in its main payment processing service. A $100 million product Analysts generally agree the Square Card is well on its way to becoming a $100 million product. Where they disagree is how long it will take for it to get there.

  • Inovio narrows focus, eliminates 80 jobs
    American City Business Journals

    Inovio narrows focus, eliminates 80 jobs

    Inovio Pharmaceuticals Inc. said it plans to narrow its drug development focus in a move that will result in the elimination of 80 positions, or about 28 percent of the Montgomery County biotechnology company's total workforce. Going forward, Inovio (NASDAQ: INO) said it has "sharpened its corporate strategy" to concentrate on the commercial development of its late-stage drugs candidates targeting the human papillomavirus (HPV) and reallocate capital to develop fast-to-market product candidates. The Plymouth Meeting company has cut selected early-stage research and development programs and discontinued further development of its advanced bladder cancer therapy candidate in early development.

  • Business

    Nu Skin stock falls after outlook cut on China sales

    Nu Skin Enterprises Inc. (nus) shares fell in the extended session Tuesday after the beauty and wellness products maker cut its outlook. Nu Skin shares fell 14% after hours, following a 3.4% rise to close the regular session at $45.51. "We are adjusting our guidance for the year primarily due to a reduced revenue outlook in Mainland China following the government's 100-day campaign to review and inspect the health products and direct selling industries," said Nu Skin Chief Executive Ritch Wood in a statement.

  • Microsoft, AT&T ink cloud deal worth more than $2 billion

    Microsoft, AT&T ink cloud deal worth more than $2 billion

    Microsoft Corp and AT&T Inc on Wednesday said they reached a deal under which the telecommunications firm will tap Microsoft's Azure cloud service for its computing needs and provide Office 365 software to much of its 268,000-strong workforce. Under the deal, Microsoft and AT&T will also work together on so-called edge computing, which will see Microsoft technology deployed alongside AT&T's coming 5G network for applications that need extremely small delays in passing data back and forth, such as air traffic control systems for drones. The multi-year deal is worth more than $2 billion, according to a person familiar with the matter.

  • Why Western Digital, Turquoise Hill Resources, and Range Resources Slumped Today
    Motley Fool

    Why Western Digital, Turquoise Hill Resources, and Range Resources Slumped Today

    Wall Street started the latest earnings season on a fairly downbeat note, with the S&P 500 and Nasdaq Composite both seeing small declines even as the Dow Jones Industrial Average fell by a more modest percentage. Western Digital (NASDAQ: WDC), Turquoise Hill Resources (NYSE: TRQ), and Range Resources (NYSE: RRC) were among the worst performers. Shares of Western Digital dropped 6% after comments about another major player in the memory space seemed to reflect poorly on it.

  • JP Morgan, Goldman Sachs, Wells Fargo beat on Q2 earnings
    Yahoo Finance Video

    JP Morgan, Goldman Sachs, Wells Fargo beat on Q2 earnings

    Major banks JP Morgan, Wells Fargo and Goldman Sachs are out with Q2 earnings that beat expectations. Yahoo Finance's Brian Cheung joins Seana Smith on 'The Ticker' to discuss.

  • About to Buy Penny Stocks? Look at These 3 Companies First
    Motley Fool

    About to Buy Penny Stocks? Look at These 3 Companies First

    Three high-upside options that these Motley Fool contributors think offer a far greater probability of earning fat returns than a penny stock are pharmaceutical company Axsome Therapeutics (NASDAQ: AXSM), oil and gas producer Chesapeake Energy (NYSE: CHK), and wind blade maker TPI Composites (NASDAQ: TPIC). Here's what we find intriguing about these high-risk, high-reward stocks. High risk, high reward Maxx Chatsko (Axsome Therapeutics): Any individual investor (mistakenly) dreaming of striking it rich with penny stocks should instead consider Axsome Therapeutics.

  • A $4.2 Billion Bid to Crash a Private Equity Party Fails

    A $4.2 Billion Bid to Crash a Private Equity Party Fails

    On Monday, the supplier to Apple Inc. made a short-lived, 3.7 billion-euro ($4.2 billion) effort to snatch Osram Licht AG from private equity firms Bain Capital and Carlyle Group LP, which had sewn up a lower-priced takeover of the German lighting-maker earlier this month. The abortive effort will underscore investor concerns about the company's strategy under Chief Executive Officer Alexander Everke. The flirtation with Osram was short and not particularly sweet.

  • Business

    Cannabis company Curaleaf to buy GR Cos. in a cash and stock deal valued at $875 million

    Massachusetts-based cannabis company Curaleaf Holdings Inc. curlf)(ca:cura) said Wednesday it was buying multi-state operator GR Companies Inc. in a deal valued at $875 million in cash and stock.

  • Oil Rises as U.S. Trade and Iran Tensions Linger Over Market

    Oil Rises as U.S. Trade and Iran Tensions Linger Over Market

    U.S. President Donald Trump reiterated that he could impose additional duties on Beijing if he wants after agreeing to a trade-war truce with his counterpart Xi Jinping last month. Secretary of State Mike Pompeo said Iran indicated it would be open to talks if some conditions were met. U.S. inventory figures were mixed as crude stockpiles fell, but that was offset by a large rise in distillates, the American Petroleum Institute reported.

  • Imagine Owning Halliburton (NYSE:HAL) While The Price Tanked 69%
    Simply Wall St.

    Imagine Owning Halliburton (NYSE:HAL) While The Price Tanked 69%

    To wit, the Halliburton Company (NYSE:HAL) share price managed to fall 69% over five long years. The falls have accelerated recently, with the share price down 28% in the last three months. While markets are a powerful pricing mechanism, share prices reflect investor sentiment, not just underlying business performance.

  • Gilead's Galapagos Deal: What It Means for Investors
    Motley Fool

    Gilead's Galapagos Deal: What It Means for Investors

    Anyone wondering what the first major move of Gilead Sciences' (NASDAQ: GILD) new CEO would be now has an answer. On Sunday, Daniel O'Day announced that the biotech had entered into what it called "a transformative research and development collaboration" with Galapagos NV (NASDAQ: GLPG). Gilead Sciences is shelling out $3.95 billion up front and making a $1.1 billion equity investment in Galapagos.

  • Business

    Ladenburg Thalmann initiates coverage of cannabis sector with buy ratings on Canopy Growth, Aurora

    Ladenburg Thalmann initiated coverage of the cannabis sector on Wednesday, assigning buy ratings to market leader Canopy Growth Corp. (cgc)(ca:weed) and Aurora Cannabis Inc. (acb)(ca:acb) and a neutral rating to Tilray Inc. (tlry) Analyst Glenn Mattson said he favors Canadian companies who are focused on long-term value creation and gaining market share, along with those with clear plans to enter the U.S. market, which is expected to become the world's biggest, if and when federal laws allow it. The analyst views Canopy as a compelling investment opportunity, and said he expects it to retain its leading position in Canada--and beyond. "We believe that Canopy can replicate that effort in other markets as those markets move toward legalization," Mattson wrote.

  • Forget GE -- This Restructuring Industrial Giant Is a Better Buy
    Motley Fool

    Forget GE -- This Restructuring Industrial Giant Is a Better Buy

    Making the right moves Eaton recently made a big move to spin off its lighting business. This unit has been struggling for a number of years as competition has heated up for highly efficient lighting systems driven by LED lights. Margins in the division have been weak and Eaton was actually passing up opportunities because it didn't believe the bidding prices were rational.

  • 'Mass layoffs' are down in North Carolina in 2019, records show
    American City Business Journals

    'Mass layoffs' are down in North Carolina in 2019, records show

    Quietly, Big Blue closed the doors at a site on Cornwallis Road, a move that meant more than 300 pink slips in January. In Wake County, just two layoff notifications were for cuts of 100 employees or more. More than a dozen companies disclosed notices of 100 layoffs or more to the state of North Carolina in the first half of 2019, according to a review of public records provided by the North Carolina Department of Commerce.